Filgotinib
- Generic Name
- Filgotinib
- Brand Names
- Jyseleca
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N5O3S
- CAS Number
- 1206161-97-8
- Unique Ingredient Identifier
- 3XVL385Q0M
- Background
Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases. The disease is associated with extra-articular manifestations, progressive disability, and comorbidities including cardiovascular disease and mental disorders. 50-70% of patients with RA are...
- Indication
Filgotinib is indicated for the treatment of active moderate to severe rheumatoid arthritis alone or in combination with methotrexate. Filgotinib is currently reserved for patients who are unable to tolerate or who have not responded adequately to one or more disease-modifying anti-rheumatic drugs (DMARDS).
...
- Associated Conditions
- Active, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Ulcerative Colitis
- Associated Therapies
- -
Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 1173
- Registration Number
- NCT02914535
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸University of Miami Crohn's and Colitis Center, Miami, Florida, United States
🇺🇸Cordova Research Institute, Miami, Florida, United States
Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 1188
- Registration Number
- NCT02914600
- Locations
- 🇺🇸
NYU Langone Long Island Clinical Research Associates, Great Neck, New York, United States
🇺🇸Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸Kelsey-Seybold Clinic, Houston, Texas, United States
Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 1351
- Registration Number
- NCT02914522
- Locations
- 🇺🇸
Digestive Health Specialists of the Southeast, Dothan, Alabama, United States
🇷🇺State Healthcare Institution "Regional Clinical Hospital", Saratov, Russian Federation
🇷🇺State Autonomous Health Institution of the Tyumen Region "Multidisciplinary Consultative and Diagnostic Center", Tyumen, Russian Federation
Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
- Conditions
- Interventions
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 1759
- Registration Number
- NCT02889796
Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy
- Conditions
- Interventions
- First Posted Date
- 2016-09-01
- Last Posted Date
- 2021-06-01
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 1252
- Registration Number
- NCT02886728
Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate
- Conditions
- Interventions
- First Posted Date
- 2016-08-31
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 83
- Registration Number
- NCT02885181
- Locations
- 🇺🇸
Center For Arthritis and Osteoporosis, Elizabethtown, Kentucky, United States
🇺🇸Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
🇺🇸Albuquerque Center For Rheumatology, Albuquerque, New Mexico, United States
Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment
- Conditions
- Interventions
- First Posted Date
- 2016-08-22
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 449
- Registration Number
- NCT02873936
Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants
- First Posted Date
- 2014-02-19
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 739
- Registration Number
- NCT02065700
- Locations
- 🇺🇦
Municipal Non-profit Enterprise Consultative and Diagnostic Center of Pechersk District of Kiev city, Kyiv, Ukraine
🇺🇦L.T. Malaya Therapy Institute of National Academy of Medical Sciences of Ukraine, Kharkiv, Ukraine
🇺🇦Kherson City Clinical Hospital N. A. Afanasii and Olga Tropin, Kherson, Ukraine
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.